Meeting
2024 ASCO Annual Meeting
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.
Presenter
Xiaoyu Li, MD
Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, State Key Laboratory of Biotherapy, Sichuan University
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT04337463
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5509)
DOI
10.1200/JCO.2024.42.16_suppl.5509
Abstract #
5509
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).
Speaker: James F. Spicer, PhD, FRCP
Videos & Slides
2024 ASCO Annual Meeting
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.
Speaker: Jia (Jenny) Liu, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.
Speaker: Neil Howard Segal, MD, PhD